Hantech Bio-Technology (1294) is a TW-listed Consumer Defensive company in Packaged Foods with a market capitalization of NT
.7B, trading at NT$56.40 on the TWO. This SniperIQ fundamentals page covers Hantech Bio-Technology's valuation (P/E 11.8x, P/B 2.0x), profitability (net margin 18.0%), revenue (NT$779M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market CapNT
.7B
P/E (TTM)11.8x
Net Margin18.0%
Revenue (FY25)NT$779M
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is Hantech Bio-Technology's market cap?
Hantech Bio-Technology (1294) has a market capitalization of approximately NT
.7B, trading at NT$56.40 on the TWO. Market cap moves with the live share price.
What is Hantech Bio-Technology's P/E ratio?
Hantech Bio-Technology's trailing twelve-month P/E ratio is 11.8x, with a price-to-book (P/B) of 2.0x. Valuation multiples are best compared with Consumer Defensive sector peers rather than read in isolation.
How profitable is Hantech Bio-Technology?
Hantech Bio-Technology runs a net profit margin of 18.0%, a gross margin of 37.0%, and an operating margin of 22.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Hantech Bio-Technology generate?
Hantech Bio-Technology reported revenue of NT$779M for fiscal year 2025, with net income of NT
39M and earnings per share (EPS) of 4.6. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Hantech Bio-Technology pay a dividend?
Hantech Bio-Technology offers a trailing dividend yield of about 5.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Hantech Bio-Technology financially healthy?
Hantech Bio-Technology carries a debt-to-equity ratio of 0.13x and a current ratio of 2.71x, with a market beta of -0.33. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Hantech Bio-Technology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Hantech Bio-Technology (1294) the key facts are: market cap NT
.7B, P/E 11.8x, revenue NT$779M, 52-week range 55-79.41666. Weigh valuation, profitability, growth, and balance-sheet strength against Consumer Defensive peers and form your own view.
Track Hantech Bio-Technology's full fundamentals live
Get Hantech Bio-Technology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.